Phase 2 Oesophageal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to give written consent and understand what the study involves, including its purpose and potential risks
- Adults aged 18 or older at the time of screening
- People with a life expectancy of at least 3 months
- People whose cancer has been confirmed by laboratory testing (tissue or cell sample) and cannot be surgically removed, has spread, or has come back
- People whose cancer has stopped responding to standard treatments, or who cannot tolerate or have declined standard treatments (including immunotherapy and targeted therapies), as determined by the lead doctor
- People with one of the following cancer types: head and neck squamous cell carcinoma; small-cell lung cancer, non-small cell lung cancer, or esophageal cancer; stomach, liver, bowel, or pancreatic cancer; bladder, kidney, or prostate cancer; ovarian or uterine cancer; breast cancer; or melanoma
- People whose cancer can be measured or assessed using standard imaging guidelines (RECIST v1.1)
- People who are generally able to carry out daily activities with little or no limitation (confirm with trial site regarding specific fitness level accepted)
- People whose liver, kidney, blood, and clotting functions meet the required levels as measured by blood tests (confirm with trial site for specific values)
- Women who are either not able to become pregnant (due to surgery or menopause), or who test negative for pregnancy and agree to use effective contraception for 90 days after receiving the study treatment
- Men who agree not to donate sperm and to use appropriate contraception for 90 days after receiving the study treatment
- People with suitable veins for blood draws
- People who are willing and able to follow all study procedures and requirements
Who may not be able to join:
- People who are still experiencing side effects from previous treatments that are moderate or severe in nature (with some exceptions such as hair loss, tiredness, mild nerve symptoms, or managed hormonal conditions)
- People with serious heart conditions, a heart attack within the past 6 months, an unstable heart rhythm, or signs of reduced blood supply to the heart on an electrical heart test
- People whose heart's electrical activity (measured by a specific interval on a heart tracing) is above a certain threshold (confirm with trial site for exact values)
- People with an active infection (bacterial, viral, or fungal) that requires ongoing treatment taken throughout the body
- People who need to take corticosteroids or other medicines that suppress the immune system and cannot stop taking them at least 14 days before the study treatment begins
- People who have received certain recent treatments within specified time periods, including: immune checkpoint inhibitors or biological therapies within the past 28 days; cancer treatments, surgery, radiation, or radiopharmaceuticals within the past 21 days; unapproved experimental drugs within a set timeframe based on the drug; or certain chemotherapy agents (nitrosoureas or mitomycin C) within the past 6 weeks
- People who have had another separate cancer within the past 5 years, with some exceptions for certain low-risk cancers (confirm with trial site)
- People who are pregnant or breastfeeding
- People with known HIV, active hepatitis B, or hepatitis C infection
- People who are unable or unwilling to follow the study procedures
- People with a history of severe allergic reactions that could interfere with participation
- People with significant ongoing disease affecting the heart, lungs, liver, kidneys, blood, digestive system, hormones, nervous system, mental health, or immune system within the past 6 months
- People with conditions that could affect how the body processes the study drug
- People who have received a live vaccine within 28 days before screening
- People who are currently taking part in another clinical trial or did so within 30 days before screening
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 16466173088
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of participants with treatment-emergent adverse events; To evaluate the safety and tolerability of SL-28 by determining the incidence of dose-limiting toxicitieswithin the first 28 days after infusion.; Change from baseline in ECG QT interval; Change from baseline in vital signs; Change from baseline in vital signs; Change from baseline in vital signs; Number of participants with dose-limiting toxicities (DLTs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.